Illumina Genome Analyzer II

Illumina 基因组分析仪 II

• 批准号: 7595573
• 负责人: George S. Grills
• 金额: $ 49.5万
• 依托单位: CORNELL UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-04-01 至 2010-09-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7595573
• 关键词: Biological Sciences; Candidate Disease Gene; Core Facility; DNA Resequencing; DNA Sequence; Disease; Funding; Funding Agency; Future; Gene Expression; Genes; Genome; Genotype; Health; Immune response; Infertility; Informatics; Information Technology; Knowledge; Laboratories; Listeria; Lung diseases; Malaria; Malignant Neoplasms; Mammary gland; Measurement; Mutation; Mutation Detection; Mycobacterium tuberculosis; Neural Tube Defects; Ovarian; Patients; Play; Prostate; Proteins; Regulation; Research; Research Personnel; Research Project Grants; Resistance; Resource Sharing; Resources; Role; Running; SNP genotyping; Sampling; Services; Small RNA; Stem cells; Streptococcus; System; Technology; United States National Institutes of Health; Universities; cost; cost effective; experience; genome-wide; instrument; insulin signaling; meetings; multidisciplinary; neuropsychiatry; new technology; pathogenic bacteria; public health relevance; research study

DESCRIPTION (provided by applicant): The introduction of new DNA sequencing technologies presents an exceptional opportunity for creative applications with potential for breakthrough discoveries. Funding is requested for an Illumina Genome Analyzer II (GAII, also called an Illumina Solexa). The instrument will be located in the Cornell University Life Sciences Core Laboratories Center (CLC). The instrument system will be operated with a multidisciplinary, multi-core approach, including support from the DNA sequencing, genotyping, microarrays, information technology and informatics core resources of the Center. Implementation of the Illumina Solexa in a core facility center as a shared resource will enable cost effective access to this vital new technology. The CLC has significant experience in running the requested instrument system. The CLC has had an Illumina Solexa since July 2007 and currently offers this platform as a standard core facility service. This instrument was purchased with non-NIH funding sources. There is a significant backlog on this instrument and projected throughput demand exceeds the capacity of the instrument. To meet demand, a second Illumina Solexa unit has been in the CLC since December 2007, on loan at no cost for six months. Due to the projected high level of use for NIH funded projects, NIH funding is requested for purchase of a second Illumina Solexa instrument. There is a clear need for a second Illumina Solexa instrument to be permanently placed at Cornell as a shared resource. This application describes 19 projects from 21 NIH funded investigator groups that will utilize the instrument. The Illumina Solexa will be used for whole genome assembly, resequencing of PCR amplicons, mutation detection (including sequencing large sets of patient samples to identify mutations in disease candidate genes), SNP genotyping, genome-wide measurements of protein-nucleic interactions, and small RNA profiling for gene expression and gene regulation studies. The Illumina Solexa makes possible experiments that are impractical or impossible with conventional sequencing instruments. The requested instrument will enable NIH funded investigators at Cornell to undertake research projects that would not otherwise be possible. The instrument will facilitate a broad range of current and future NIH funded projects. PUBLIC HEALTH RELEVANCE: The requested Illumina Solexa instrument will play a crucial role in advancing knowledge and understanding in a wide variety of health related research, including studies of cancer transformation (hematologic, ovarian, prostate and mammary malignancies), insulin signaling, immune response, pulmonary disease, neural tube defects, stem cell potential, infertility, neuropsychiatric disease, malaria resistance, and pathogenic bacteria (M. tuberculosis, Streptococcus, and Listeria).

描述(由申请人提供)：新的DNA测序技术的引入为具有突破性发现潜力的创造性应用提供了一个特殊的机会。为Illumina Genome Analyzer II(GAII，也称为Illumina Solexa)申请资金。该仪器将安装在康奈尔大学生命科学核心实验室中心(CLC)。该仪器系统将以多学科、多核心方式运作，包括中心的DNA测序、基因分型、微阵列、信息技术和信息学核心资源的支持。将Illumina Solexa作为共享资源在核心设施中心实施，将使人们能够经济高效地使用这项至关重要的新技术。《中图法》在运行所要求的仪器系统方面拥有丰富的经验。CLC自2007年7月以来一直拥有Illumina Solexa，目前将该平台作为标准核心设施服务提供。该仪器是用非NIH资金来源购买的。这台仪器有大量积压，预计的吞吐量需求超过了仪器的能力。为了满足需求，Illumina Solexa的第二个单元自2007年12月以来一直在CLC免费借用，为期六个月。由于国家卫生研究院资助的项目预计使用量很高，因此要求国家卫生研究院提供资金用于购买第二台Illumina Solexa仪器。显然需要将第二台Illumina Solexa仪器作为共享资源永久放置在康奈尔大学。这份申请描述了来自21个NIH资助的研究小组的19个项目，这些项目将使用该仪器。Illumina Solexa将用于全基因组组装、对PCR扩增片段重新排序、突变检测(包括对大量患者样本进行测序以确定疾病候选基因的突变)、SNP基因分型、全基因组蛋白质-核相互作用的测量，以及用于基因表达和基因调控研究的小RNA图谱。Illumina Solexa使传统测序仪器不实用或不可能进行的实验成为可能。所要求的仪器将使美国国立卫生研究院资助的康奈尔大学的研究人员能够进行原本不可能进行的研究项目。该文书将促进一系列目前和未来由国家卫生研究院资助的项目。公共卫生相关性：所需的Illumina Solexa仪器将在促进各种健康相关研究中的知识和理解方面发挥关键作用，包括癌症转化(血液、卵巢、前列腺和乳腺恶性肿瘤)、胰岛素信号、免疫反应、肺部疾病、神经管缺陷、干细胞潜力、不孕不育、神经精神疾病、疟疾耐药性和病原菌(结核杆菌、链球菌和李斯特菌)的研究。